Levophenacylmorphan is a morphinan derivative that acts as an opioid agonist. It has potent analgesic effects and is around 10x more potent than morphine.[2] Adverse effects associated with its use are those of the opioids as a whole, including pruritus, nausea, respiratory depression, euphoria and development of tolerance and dependence to its effects.[3]
Clinical data | |
---|---|
Other names | Levophenacylmorphan |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.030.168 |
Chemical and physical data | |
Formula | C24H27NO2 |
Molar mass | 361.485 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
See also
editReferences
edit- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ May E, Eddy N (February 1959). "A New Potent Synthetic Analgesic". Communications. The Journal of Organic Chemistry. 24 (2): 294–5. doi:10.1021/jo01084a655.
- ^ Fraser HF, Isbell H (January 1960). "Human pharmacology and addiction liabilities of phenazocine and levophenacylmorphan". Bulletin on Narcotics. 12 (2): 15–23.